UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 01, 2007
-------------------
HENRY SCHEIN, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-27078 11-3136595
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission File IRS Employer
of incorporation) Number) (Identification No.)
135 DURYEA ROAD, MELVILLE, NEW YORK 11747
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (631) 843-5500
-----------------
NOT APPLICABLE
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On November 01, 2007, Henry Schein, Inc. issued a press release reporting
the financial results for the three and nine months ended September 29, 2007.
The full text of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(a) Not applicable.
(b) Not applicable.
(c) Not applicable.
(d) Exhibit 99.1 - Press Release dated November 01, 2007.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
HENRY SCHEIN, INC.
By: /s/ Steven Paladino
------------------------------------
Steven Paladino
Executive Vice President,
Chief Financial Officer and Director
(principal financial and accounting
officer)
November 01, 2007
EXHIBIT INDEX
Exhibit No. Description
99.1 Press Release dated November 01, 2007.
HENRY SCHEIN
NEWS RELEASE
Henry Schein, Inc. - 135 Duryea Road - Melville, New York 11747
FOR IMMEDIATE RELEASE
HENRY SCHEIN REPORTS STRONG THIRD QUARTER RESULTS
EPS from continuing operations increase 50% to $0.66
Company introduces 2008 EPS guidance
MELVILLE, N.Y. - November 1, 2007 - Henry Schein, Inc. (NASDAQ: HSIC), the
largest provider of healthcare products and services to office-based
practitioners in the combined North American and European markets, today
reported financial results for the quarter ended September 29, 2007.
Net sales for the third quarter of 2007 were $1.5 billion, an increase
of 20.8% compared with the third quarter of 2006. This increase includes 18.3%
local currency growth (13.0% internally generated and 5.3% from acquisitions)
and 2.5% related to foreign currency exchange. (See Exhibit A for details of
sales growth.)
Income from continuing operations for the third quarter of 2007 was
$60.7 million or $0.66 per diluted share, up 54.6% and 50.0%, respectively,
compared with the prior year third quarter. Income from continuing operations
includes a pretax gain related to the disposition of certain assets of $2.4
million or $0.02 per diluted share.
Net income for the third quarter of 2007 was $59.6 million or $0.65 per
diluted share. Results include a loss from discontinued operations of $1.1
million or $0.01 per diluted share primarily related to the sale of the
company's oncology pharmaceutical business.
"We are very pleased with our third quarter financial results, which
once again reflect strong double-digit sales growth and market-share gains in
each of our four business groups," said Stanley M. Bergman, Chairman and Chief
Executive Officer of Henry Schein. "Our Dental Group continued its trend of
mid-teens growth while our Medical, International and Technology Groups each
posted sales gains well in excess of 20% for the quarter."
Dental Group sales increased 14.6% during the third quarter, including
13.8% growth in local currencies (10.4% internally generated and 3.4% from
acquisitions) and 0.8% growth related to
1
- more -
foreign currency exchange. Of the 13.8% local currency growth, Dental
consumable merchandise sales increased 9.9% (6.0% internal growth and 3.9%
acquisition growth) and Dental equipment sales and service revenues were up
25.9% (24.1% internal growth and 1.8% acquisition growth).
"Our Dental Group reported impressive internal growth in consumable
merchandise and equipment sales and service revenues, with strong gains in both
basic equipment and high-tech products," commented Mr. Bergman. "Of note, we
have completed the integration of the full-service and special markets
businesses of Becker-Parkin Dental Supply acquired in July, which strengthens
our presence in key geographies."
Medical Group sales increased 25.0% during the third quarter (22.5%
internal growth and 2.5% acquisition growth). Excluding sales of influenza
vaccine, Medical Group sales increased 9.0%, with 6.9% internal growth.
"We are pleased with the strong performance of our Medical Group, which
reflects the positive impact of our Medical One World program as well as the
sale of approximately 7.3 million doses of flu vaccine, among other factors,"
said Mr. Bergman.
For the quarter, International Group sales increased 25.7%, including
17.4% growth in local currencies (6.9% internally generated and 10.5% from
acquisitions) and 8.3% related to foreign currency exchange.
"Our International Group posted across-the-board gains with particular
strength in the U.K., Italy, Spain and the Benelux countries," commented Mr.
Bergman. "During the third quarter we acquired W. & J. Dunlop, a leading U.K.
animal health products supplier. With the addition of Dunlops, our worldwide
veterinary business is at a run-rate of more than $700 million in annual sales."
Technology and Value-Added Services Group sales increased 29.5% during
the third quarter of 2007, including 29.0% growth in local currencies (15.5%
internally generated and 13.5% acquisition growth) and 0.5% growth related to
foreign currency exchange.
"Technology and Value-Added Services results reflect continued strong
electronic services, software and financial services revenue growth," stated Mr.
Bergman. "We recently closed on our acquisition of Software of Excellence,
which provides us with leading positions in the U.K., Australia and New Zealand
dental practice software markets. Sales of these products will be included in
our Technology and Value-Added Services Group beginning with the fourth quarter
of 2007."
2
-more-
Year-to-Date Results
For the first nine months of 2007, net sales of $4.2 billion represent
an increase of 17.6% compared with the first nine months of 2006. This increase
includes 15.2% local currency growth (8.8% internally generated and 6.4% from
acquisitions net of divestiture) and 2.4% related to foreign currency exchange.
Income from continuing operations for the first nine months of 2007 was $158.5
million or $1.75 per diluted share, up 32.4% and 30.6%, respectively, compared
with the first nine months of 2006.
2007 EPS Guidance
Henry Schein affirms 2007 financial guidance from continuing
operations, as follows:
o 2007 diluted EPS is expected to be $2.53 to $2.57.
o This 2007 diluted EPS guidance includes Henry Schein's new expectation
that it will distribute approximately 15.5 million doses of influenza
vaccine during the year, compared with prior expectations it would
distribute approximately 20 million doses.
o 2007 diluted EPS guidance includes completed or previously announced
acquisitions and does not include the impact of potential future
acquisitions, if any.
2008 EPS Guidance
Henry Schein introduces 2008 financial guidance, as follows:
o 2008 diluted EPS is expected to be $2.93 to $3.00. This represents an
increase of 15% to 18% compared with the mid-point of the Company's
2007 diluted EPS guidance.
o This 2008 diluted EPS guidance includes Henry Schein's expectation
that it will distribute 12 to 15 million doses of influenza vaccine
during the year, representing $0.13 to $0.16 per diluted share.
o 2008 diluted EPS guidance is for current continuing operations
including completed or previously announced acquisitions, and does not
include the impact of potential future acquisitions, if any.
Third Quarter Conference Call Webcast
The Company will hold a conference call to discuss third quarter
financial results today, beginning at 10:00 a.m. Eastern time. Individual
investors are invited to listen to the conference call over the Internet through
Henry Schein's Web site at www.henryschein.com. In addition, a replay will be
available beginning shortly after the call has ended.
3
- more -
About Henry Schein
Henry Schein, a Fortune 500(R) company and a member of the NASDAQ
100(R) Index, is recognized for its excellent customer service and highly
competitive prices. The Company's four business groups - Dental, Medical,
International and Technology - serve more than 500,000 customers worldwide,
including dental practitioners and laboratories, physician practices and animal
health clinics, as well as government and other institutions. The Company
operates through a centralized and automated distribution network, which
provides customers in more than 200 countries with a comprehensive selection of
more than 85,000 national and Henry Schein private-brand products in stock, as
well as more than 100,000 additional products available as special-order items.
Henry Schein also offers a wide range of innovative value-added
practice solutions for healthcare professionals, such as ArubA(R), the Company's
electronic catalog and ordering system. Its leading practice-management
software solutions have been installed in more than 50,000 practices, including
DENTRIX(R) and Easy Dental(R) for dental practices, MicroMd(R) for physician
practices, and AVImark(R) for animal health clinics.
Headquartered in Melville, N.Y., Henry Schein employs nearly 12,000
people and has operations or affiliates in 22 countries. The Company's net
sales reached a record $5.05 billion in 2006. For more information, visit the
Henry Schein Web site at www.henryschein.com.
In accordance with the "Safe Harbor" provisions of the Private Securities
Litigation Reform Act of 1995, we provide the following cautionary remarks
regarding important factors which, among others, could cause future results to
differ materially from the forward-looking statements, expectations and
assumptions expressed or implied herein. All forward-looking statements made by
us are subject to risks and uncertainties and are not guarantees of future
performance. These forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance
and achievements, or industry results to be materially different from any future
results, performance or achievements expressed or implied by such forward-
looking statements. These statements are identified by the use of such terms as
"may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast,"
"project," "anticipate" or other comparable terms. A full discussion of our
operations and financial condition, including factors that may affect our
business and future prospects, is contained in documents we have filed with the
SEC and will be contained in all subsequent periodic filings we make with the
SEC. These documents identify in detail important risk factors that could cause
our actual performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to differ
materially from current and historical results include, but are not limited to:
competitive factors; changes in the healthcare industry; changes in government
regulations that affect us; financial risks associated with our international
operations; fluctuations in quarterly earnings; our dependence on third parties
for the manufacture and supply of our products; transitional challenges
associated with acquisitions; financial risks associated with acquisitions;
regulatory and litigation risks; the dependence on our continued product
development, technical support and successful marketing in the technology
segment; our dependence upon sales personnel and key customers; our dependence
on our senior management; possible increases in the cost of shipping our
products or other service trouble with our third-party shippers; risks from
rapid technological change; risks from potential increases in variable interest
rates; possible volatility of the market price of our common stock; certain
provisions in our governing documents that may
4
- more -
discourage third-party acquisitions of us; and changes in tax legislation that
affect us. The order in which these factors appear should not be construed to
indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many of these
factors are beyond our ability to control or predict. Accordingly, forward-
looking statements should not be relied upon as a prediction of actual results.
We undertake no duty and have no obligation to update forward-looking
statements.
(TABLES TO FOLLOW)
5
- more -
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
(unaudited)
Three Months Ended Nine Months Ended
----------------------------- -----------------------------
September 29, September 30, September 29, September 30,
2007 2006 2007 2006
------------- ------------- ------------- -------------
Net sales .................................................... $ 1,505,575 $ 1,246,553 $ 4,202,720 $ 3,573,127
Cost of sales ................................................ 1,076,245 887,495 2,968,567 2,521,303
------------- ------------- ------------- -------------
Gross profit .......................................... 429,330 359,058 1,234,153 1,051,824
Operating expenses:
Selling, general and administrative ...................... 332,630 296,457 972,880 852,228
------------- ------------- ------------- -------------
Operating income ...................................... 96,700 62,601 261,273 199,596
Other income (expense):
Interest income .......................................... 4,378 3,485 12,766 11,980
Interest expense ......................................... (6,216) (6,504) (18,381) (21,107)
Other, net (includes $2.4 million gain in 2007) .......... 3,917 2,294 4,342 2,165
------------- ------------- ------------- -------------
Income from continuing operations before
taxes, minority interest and equity in
earnings (losses) of affiliates ...................... 98,779 61,876 260,000 192,634
Income taxes ................................................. (33,682) (21,695) (89,788) (69,062)
Minority interest in net income of subsidiaries .............. (4,247) (1,181) (11,004) (4,447)
Equity in earnings (losses) of affiliates .................... (182) 246 (687) 581
------------- ------------- ------------- -------------
Income from continuing operations ............................ 60,668 39,246 158,521 119,706
Discontinued operations:
Income (loss) from operations of discontinued
components (including write-down of long-lived assets
of $32.7 million in 2007 and a loss on sale of
discontinued operation of $1.5 million and $32.3
million in 2007 and 2006, respectively) .............. (1,742) 59 (34,302) (31,601)
Income tax benefit (expense) ............................. 647 (20) 12,685 12,657
------------- ------------- ------------- -------------
Income (loss) from discontinued operations ............... (1,095) 39 (21,617) (18,944)
------------- ------------- ------------- -------------
Net income ................................................... $ 59,573 $ 39,285 $ 136,904 $ 100,762
============= ============= ============= =============
Earnings from continuing operations per share:
Basic .................................................... $ 0.68 $ 0.44 $ 1.79 $ 1.36
============= ============= ============= =============
Diluted .................................................. $ 0.66 $ 0.44 $ 1.75 $ 1.34
============= ============= ============= =============
Loss from discontinued operations per share:
Basic .................................................... $ (0.01) $ 0.00 $ (0.24) $ (0.21)
============= ============= ============= =============
Diluted .................................................. $ (0.01) $ 0.00 $ (0.24) $ (0.21)
============= ============= ============= =============
Earnings per share:
Basic .................................................... $ 0.67 $ 0.44 $ 1.55 $ 1.15
============= ============= ============= =============
Diluted .................................................. $ 0.65 $ 0.44 $ 1.51 $ 1.13
============= ============= ============= =============
Weighted-average common shares outstanding:
Basic .................................................... 88,790 88,291 88,383 87,820
============= ============= ============= =============
Diluted .................................................. 91,399 90,015 90,779 89,554
============= ============= ============= =============
Note: The above prior period amounts have been restated to reflect the effects
of our discontinued operations.
6
- more -
HENRY SCHEIN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
September 29, December 30,
2007 2006
------------- -------------
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents .................................................. $ 207,458 $ 248,647
Available-for-sale securities............................................... 27,750 47,999
Accounts receivable, net of reserves of $42,006 and $40,536 ................ 764,590 610,020
Inventories, net ........................................................... 676,557 584,103
Deferred income taxes ...................................................... 31,742 28,240
Prepaid expenses and other ................................................. 145,372 125,839
------------- -------------
Total current assets ............................................... 1,853,469 1,644,848
Property and equipment, net .................................................... 236,309 225,038
Goodwill ....................................................................... 887,285 773,801
Other intangibles, net ......................................................... 203,389 161,542
Investments and other .......................................................... 103,041 75,917
------------- -------------
Total assets ....................................................... $ 3,283,493 $ 2,881,146
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable ........................................................... $ 514,830 $ 414,062
Bank credit lines .......................................................... 2,856 2,528
Current maturities of long-term debt ....................................... 29,050 41,036
Accrued expenses:
Payroll and related ..................................................... 122,898 110,401
Taxes ................................................................... 77,882 59,007
Business acquisition .................................................... 61,615 --
Other ................................................................... 204,760 183,054
------------- -------------
Total current liabilities .......................................... 1,013,891 810,088
Long-term debt ................................................................. 432,279 455,806
Deferred income taxes ........................................................... 71,916 62,334
Other liabilities .............................................................. 62,206 60,209
Minority interest .............................................................. 29,646 21,746
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized,
none outstanding ........................................................ -- --
Common stock, $.01 par value, 240,000,000 shares authorized,
89,503,384 outstanding on September 29, 2007 and
88,499,321 outstanding on December 30, 2006 ............................. 895 885
Additional paid-in capital .................................................. 665,013 614,551
Retained earnings ........................................................... 926,786 808,164
Accumulated other comprehensive income ...................................... 80,861 47,363
------------- -------------
Total stockholders' equity ......................................... 1,673,555 1,470,963
------------- -------------
Total liabilities and stockholders' equity ......................... $ 3,283,493 $ 2,881,146
============= =============
Note: The above includes $4.0 million of accounts receivable, net of reserves,
and $1.8 million of inventories, net of reserves, related to discontinued
components that are held-for-sale as of September 29, 2007.
7
- more -
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Three Months Ended
-----------------------------
September 29, September 30,
2007 2006
------------- -------------
Cash flows from operating activities:
Net income ................................................................. $ 59,573 $ 39,285
Adjustments to reconcile net income to net cash
provided by operating activities:
Loss on sale of discontinued operation, net of tax .................. 929 --
Depreciation and amortization ....................................... 17,794 16,733
Stock-based compensation expense .................................... 5,995 4,559
Impairment from write down of long-lived assets of
discontinued operations ....................................... -- --
Provision for losses on trade and other accounts receivable ......... 830 1,664
Provision for (benefit from) deferred income taxes .................. 1,958 (8,599)
Stock issued to 401(k) plan ......................................... 4,104 3,565
Undistributed earnings (losses) of affiliates ....................... 182 (246)
Minority interest in net income of subsidiaries ..................... 4,247 1,181
Other ............................................................... (2,300) (2,137)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable ........................................... (65,765) (6,395)
Inventories ................................................... (47,387) (4,212)
Other current assets .......................................... (14,310) (770)
Accounts payable and accrued expenses ......................... 103,334 19,381
------------- -------------
Net cash provided by operating activities ...................................... 69,184 64,009
------------- -------------
Cash flows from investing activities:
Purchases of fixed assets ................................................. (11,687) (17,273)
Payments for equity investment and business acquisitions,
net of cash acquired ................................................... (82,475) (80,945)
Cash received from business divestitures .................................. 5,061 --
Purchases of available-for-sale securities ................................ (27,065) (16,697)
Proceeds from sales of available-for-sale securities ...................... 87,315 117,806
Proceeds from maturities of available-for-sale securities ................. -- --
Net payments for foreign exchange forward contract settlements ............ (5,367) (2,090)
Other ..................................................................... (6,428) (6,769)
------------- -------------
Net cash used in investing activities .......................................... (40,646) (5,968)
------------- -------------
Cash flows from financing activities:
Proceeds from issuance of long-term debt .................................. -- --
Proceeds from (repayments of) bank borrowings ............................. (4,273) 297
Principal payments for long-term debt ..................................... (24,604) (24,202)
Proceeds from issuance of stock upon exercise of stock options ............ 9,099 7,300
Payments for repurchases of common stock .................................. -- (2,261)
Excess tax benefits related to stock-based compensation ................... 3,575 3,362
Other ..................................................................... (422) (384)
------------- -------------
Net cash used in financing activities .......................................... (16,625) (15,888)
------------- -------------
Net change in cash and cash equivalents ........................................ 11,913 42,153
Effect of exchange rate changes on cash and cash equivalents ................... 4,574 (4,417)
Cash and cash equivalents, beginning of period ................................. 190,971 138,334
------------- -------------
Cash and cash equivalents, end of period ....................................... $ 207,458 $ 176,070
============= =============
Nine Months Ended
-----------------------------
September 29, September 30,
2007 2006
------------- -------------
Cash flows from operating activities:
Net income ................................................................. $ 136,904 $ 100,762
Adjustments to reconcile net income to net cash
provided by operating activities:
Loss on sale of discontinued operation, net of tax .................. 929 19,363
Depreciation and amortization ....................................... 53,021 46,891
Stock-based compensation expense .................................... 16,720 13,933
Impairment from write down of long-lived assets of
discontinued operations ....................................... 32,667 --
Provision for losses on trade and other accounts receivable ......... 1,062 2,343
Provision for (benefit from) deferred income taxes .................. (16,730) (2,662)
Stock issued to 401(k) plan ......................................... 4,104 3,565
Undistributed earnings (losses) of affiliates ....................... 687 (581)
Minority interest in net income of subsidiaries ..................... 11,004 4,447
Other ............................................................... (2,870) (2,549)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable ........................................... (82,521) (9,418)
Inventories ................................................... (31,941) (35,967)
Other current assets .......................................... (9,841) 7,376
Accounts payable and accrued expenses ......................... 36,730 (82,877)
------------- -------------
Net cash provided by operating activities ...................................... 149,925 64,626
------------- -------------
Cash flows from investing activities:
Purchases of fixed assets ................................................. (33,023) (49,927)
Payments for equity investment and business acquisitions,
net of cash acquired ................................................... (124,298) (186,132)
Cash received from business divestitures .................................. 5,061 36,527
Purchases of available-for-sale securities ................................ (115,066) (164,037)
Proceeds from sales of available-for-sale securities ...................... 135,315 286,767
Proceeds from maturities of available-for-sale securities ................. -- 1,280
Net payments for foreign exchange forward contract settlements ............ (16,980) (16,895)
Other ..................................................................... (11,037) (6,604)
------------- -------------
Net cash used in investing activities .......................................... (160,028) (99,021)
------------- -------------
Cash flows from financing activities:
Proceeds from issuance of long-term debt .................................. 483 --
Proceeds from (repayments of) bank borrowings ............................. (4,554) 297
Principal payments for long-term debt ..................................... (42,529) (30,677)
Proceeds from issuance of stock upon exercise of stock options ............ 32,719 32,900
Payments for repurchases of common stock .................................. (30,689) (25,700)
Excess tax benefits related to stock-based compensation ................... 11,597 13,150
Other ..................................................................... (1,879) 1,665
------------- -------------
Net cash used in financing activities .......................................... (34,852) (8,365)
------------- -------------
Net change in cash and cash equivalents ........................................ (44,955) (42,760)
Effect of exchange rate changes on cash and cash equivalents ................... 3,766 8,147
Cash and cash equivalents, beginning of period ................................. 248,647 210,683
------------- -------------
Cash and cash equivalents, end of period ....................................... $ 207,458 $ 176,070
============= =============
8
- more -
Exhibit A
Henry Schein, Inc.
2007 Third Quarter
Sales Growth Rate Summary
(unaudited)
Q3 2007 over Q3 2006
--------------------
Consolidated Dental Medical International Technology
------------ ----------- ------------ ------------- ------------
Internal Sales Growth 13.0% 10.4% 22.5% 6.9% 15.5%
Acquisitions 5.3% 3.4% 2.5% 10.5% 13.5%
------------ ----------- ------------ ------------- ------------
Local Currency Sales Growth 18.3% 13.8% 25.0% 17.4% 29.0%
Foreign Currency Exchange 2.5% 0.8% -- 8.3% 0.5%
------------ ----------- ------------ ------------- ------------
Total Sales Growth 20.8% 14.6% 25.0% 25.7% 29.5%
============ =========== ============ ============= ============
Q3 YTD 2007 over Q3 YTD 2006
----------------------------
Consolidated Dental Medical International Technology
------------ ----------- ------------ ------------- ------------
Internal Sales Growth 8.8% 10.3% 10.5% 4.1% 19.5%
Acquisitions, net of divestiture 6.4% 5.6% 6.6% 6.8% 10.5%
------------ ----------- ------------ ------------- ------------
Local Currency Sales Growth 15.2% 15.9% 17.1% 10.9% 30.0%
Foreign Currency Exchange 2.4% 0.3% -- 8.5% 0.2%
------------ ----------- ------------ ------------- ------------
Total Sales Growth 17.6% 16.2% 17.1% 19.4% 30.2%
============ =========== ============ ============= ============
FOR: Henry Schein, Inc.
CONTACT: Steven Paladino
Executive Vice President and Chief Financial Officer
steven.paladino@henryschein.com
(631) 843-5500
Investors: Neal Goldner
Vice President, Investor Relations
neal.goldner@henryschein.com
(631) 845-2820
Media: Susan Vassallo
Vice President, Corporate Communications
susan.vassallo@henryschein.com
(631) 843-5562
9
###